<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709459</url>
  </required_header>
  <id_info>
    <org_study_id>PHIRG1901</org_study_id>
    <nct_id>NCT03709459</nct_id>
  </id_info>
  <brief_title>Impact of the Daily Doxycycline Pre-exposure Prophylaxis (PrEP) on the Incidence of Syphilis, Gonorrhoea and Chlamydia</brief_title>
  <acronym>Syphilaxis</acronym>
  <official_title>Impact of the Daily Doxycycline Pre-exposure Prophylaxis (PrEP) on the Incidence of Syphilis, Gonorrhoea and Chlamydia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South Australian Health and Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. This study is a non-randomized observational cohort trial using before and after&#xD;
      comparison to evaluate intervention 2. It would mimic the conditions that would occur outside&#xD;
      a clinical trial. 2. After consent and enrolment, all procedures will be guided by the&#xD;
      Australian STI Management Guidelines.&#xD;
&#xD;
      3. All enrolling participants will be offered daily doxycycline 100mg 4. All participants&#xD;
      will be invited to complete a survey in every 3 months time for 12 months dated from&#xD;
      participation.&#xD;
&#xD;
      5. All follow-up information will be collected through electronic data capture to allow&#xD;
      accurate and timely analyses.&#xD;
&#xD;
      6. Data collection will be from (i) medical records (ii) online self-completed questionnaire&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The last decade has seen increasing rates of bacterial STIs in Australia in gay and bisexual&#xD;
      men in particular. Although STIs are easy to diagnose and treatment is effective, untreated&#xD;
      STIs can cause significant health issues.&#xD;
&#xD;
      Previous research has shown that taking two100mg doxycycline tablets within 24 hours of sex&#xD;
      as prophylaxis reduces syphilis and chlamydia significantly. Also a pilot trial conducted in&#xD;
      the US suggested that using 100mg doxycycline as prophylaxis reduced the incidence of&#xD;
      gonorrhoea, syphilis and chlamydia. Thus the question of whether taking doxycycline daily in&#xD;
      high risk population would reduce the rate of STIs arose.&#xD;
&#xD;
      We set up this study as a non-randomized observational cohort trial using a before and after&#xD;
      comparison to evaluate if taking 100mg doxycycline daily would help high risk gay and&#xD;
      bisexual men to reduce the possibility of acquiring gonorrhoea, syphilis and chlamydia. Our&#xD;
      primary objectives are to:assess acceptability of a daily dosing regimen for doxycycline&#xD;
      prophylaxis, and measure the efficacy of 100mg daily doxycycline STI prophylaxis against&#xD;
      reinfection with gonorrhoea, chlamydia and syphilis. Our secondary objectives are to:&#xD;
      describe patterns of doxycycline use and medication adherence to the recommended schedule&#xD;
      participants; evaluate change in behavioral among all study participants; evaluate resistance&#xD;
      in the gut microbiota and in those colonized by S aureus at baseline and end of study, in a&#xD;
      subset of consenting participants.&#xD;
&#xD;
      The study will be conducted in 3 sexual health centres. Eligible participants will undergo&#xD;
      standard care in their trimonthly visit recommended by STI testing guideline, and complete&#xD;
      informed consent and a baseline survey. They will be given daily dose of 100mg oral&#xD;
      doxycycline for 3 months during the visit, and instruction of how to take the medicine.&#xD;
      Questionnaires will be sent out to participants in every 3 months electronically and data&#xD;
      will be collected and stored directly into the study survey database. Each participant will&#xD;
      be follow-up for 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Anticipated">December 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Incidence of STI (gonorrhoea, chlamydia and infectious syphilis) per 100 person years among study participants</measure>
    <time_frame>1 year after the last participant complete their last follow-up visit</time_frame>
    <description>measured using data collected by the ACCESS study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patterns of daily doxycycline use and adherence to the medication schedule</measure>
    <time_frame>1 year after the last participant complete their last follow-up visit</time_frame>
    <description>measured among participants consenting to the adherence and behavioural online survey</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evidence of clinically significant antibiotic resistance in in a subset of participants</measure>
    <time_frame>1 year after the last participant who's recruited from the Melbourne site</time_frame>
    <description>including those who do contract STIs during the study and those who don't</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioural risk practices among study participants</measure>
    <time_frame>1 year after the last participant complete their last follow-up visit</time_frame>
    <description>in participants who consent to behavioral data collection online</description>
  </secondary_outcome>
  <enrollment type="Anticipated">125</enrollment>
  <condition>STIs Prevention</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Participants will be asked to take Doxycycline 100mg/day for 12months duration</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      oropharynx and rectum swab&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men who report male to male sex in the last 3 months and who have had at least two&#xD;
        screening for syphilis, chlamydia and gonorrhoea in the last 12 months, and at least once&#xD;
        incidence of syphilis in the last two years, are eligible for the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or transgender&#xD;
&#xD;
          -  Aged 18 years or over&#xD;
&#xD;
          -  Reports sex with men in last 3 months&#xD;
&#xD;
          -  At least two screenings for syphilis, gonorrhoea and chlamydia in the past 12 months&#xD;
&#xD;
          -  A diagnosis of syphilis within the last 12 months, OR a diagnosis of any 2 STIs within&#xD;
             the last 12 months and syphilis within the last 24 months.&#xD;
&#xD;
          -  HIV +ve, OR HIV -ve and on PrEP for at least 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented or self-reported hypersensitivity to doxycycline or antimicrobial agents&#xD;
             from tetracycline family&#xD;
&#xD;
          -  A known diagnosis of myasthenia gravis&#xD;
&#xD;
          -  Factors or conditions that may compromise a participant's access to health services&#xD;
             for follow-up (incarceration or planned relocation that would impact upon proximity to&#xD;
             a trial site).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bridget Haire, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute, UNSW</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yasmin Mowat, BSc</last_name>
    <phone>+612 9385 1433</phone>
    <email>ymowat@kirby.unsw.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bridget Haire, PhD</last_name>
    <phone>+612 9385 1227</phone>
    <email>b.haire@unsw.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital Sexual Health Medicine</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linda Garton</last_name>
      <phone>02 9515 1200</phone>
      <email>Linda.Garton@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>David Templeton</last_name>
      <phone>02 9515 1200</phone>
      <email>David.Templeton@health.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kirketon Road Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Phillip Read</last_name>
      <phone>02 9360 2766</phone>
      <email>phillip.read1@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Dr Phillip Read</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Sexual Health Centre</name>
      <address>
        <city>Syd</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Anna McNulty</last_name>
      <phone>02 9382 7476</phone>
      <email>anna.mcnulty@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Dr Anna McNulty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Melbourne Sexual Health Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Eric Chow</last_name>
      <phone>03 9341 6233</phone>
      <email>EChow@mshc.org.au</email>
    </contact>
    <investigator>
      <last_name>Dr Eric Chow</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Professor Christopher K Fairley</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 12, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Syphilis, Gonorrhea, Chlamydia, Doxycycline, PrEP, Syphilaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlamydia Infections</mesh_term>
    <mesh_term>Gonorrhea</mesh_term>
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

